Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual MeetingBusiness Wire • Wednesday
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline UpdateBusiness Wire • Tuesday
Wall Street Analysts Think Arcus Biosciences, Inc. (RCUS) Could Surge 151.61%: Read This Before Placing a BetZacks Investment Research • 02/22/24
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline UpdateBusiness Wire • 02/21/24
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline UpdatesBusiness Wire • 02/07/24
Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic CancerBusiness Wire • 01/16/24
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must WatchSeeking Alpha • 01/10/24
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell CarcinomaBusiness Wire • 12/04/23
Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceBusiness Wire • 11/14/23
Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline UpdateBusiness Wire • 11/07/23
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI CancersBusiness Wire • 11/06/23
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI CancersBusiness Wire • 11/06/23
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/31/23